Key result
Standard NSAIDs cause considerable hazards resulting in ~2000 UK deaths annually.
Why the study?
Do selective cyclo-oxygenase-2 inhibitors reduce the risk of clinical ulcer complications compared to standard non-steroidal anti-inflammatory drugs in patients requiring long-term use?
Do selective cyclo-oxygenase-2 inhibitors reduce the risk of clinical ulcer complications compared to standard non-steroidal anti-inflammatory drugs in patients requiring long-term use?
Large clinical outcome studies are needed to confirm if the endoscopic benefits of selective COX-2 inhibitors translate to reduced clinical ulcer complications compared to standard NSAIDs.
No takes yet. Share an insight, caveat, or question.
NSAID mortality burden demands outcome trials; leaves open whether COX-2 inhibitors reduce clinical ulcer complications versus standard NSAIDs.
C J Hawkey (2000) conducted a review in NSAID-induced ulcers. Non-steroidal anti-inflammatory drugs was evaluated. Non-steroidal anti-inflammatory drugs cause considerable hazards, resulting in the death of up to 2000 patients a year in the United Kingdom, highlighting the need for large clinical outcome studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: